Senior Vice President, Managed Markets, Takeda Pharmaceuticals USA
Rick Ascroft is responsible for managed markets and government and external affairs and serves as a member of the Takeda Pharmaceuticals U.S.A, Inc. executive team. Mr. Ascroft joined Takeda in November 2015.
Prior to joining Takeda, Mr. Ascroft worked for Eli Lilly and Company for 22 years in a variety of clinical research, commercial, market access and corporate affairs roles. He has spent well over half of his career working in public affairs and managed markets roles in the U.S. and internationally, spending five years as the director of corporate affairs and market access for emerging markets and Japan, followed by three years as the senior director of corporate affairs and market access for the U.K. and Republic of Ireland and most recently four years as the senior director of corporate affairs, market access and pricing for Europe, Canada and Australia. Prior to these roles, Rick worked in U.S. federal public policy, clinical development and sales.
Mr. Ascroft is the author of “The Impact of the Washington Legal Foundation Cases on Pharmaceutical Manufacturer Practices in the United States,” which was published in the Indiana Law Review in 2000, and he led the industry effort to develop PhRMA’s Principles on Conduct of Clinical Trials and Communication of Clinical Trial Results. In 2009, he was part of the industry team that provided input into the U.K. Government’s Office for Life Sciences Blueprint. In 2011, he presented to the British Parliament’s Science in Parliament Committee on What is the Future for the Research-Led Pharmaceutical Industry. The proceedings were captured in the autumn 2011 Science in Parliament Journal. In 2014, he co-authored, “The Case for HTA cooperation,” in MedNous.
Mr. Ascroft has a Bachelor of Science degree in pharmacy from Butler University in Indianapolis, Indiana and a law degree from the Indiana University School of Law, graduating summa cum laude.